The use of more targeted CaMKII inhibitors in the treatment of anti-cancer drug cardiotoxicity could be an additional niche area for the pharmaceutical industry and fundamentally, could represent a new and important therapeutic approach in the field of cardio-oncology. The gene discussed is CAMK2G; the disease is cancer.